ArticleCureus2024

Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities.

Vincent Y Ng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.